Navigation Links
FDA Schedules Third Orphan Drug Workshop for Nov. 4-5, 2010
Date:10/13/2010

SILVER SPRING, Md., Oct. 13 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has scheduled the third in a series of workshops on orphan drug designation for academics, biotechnology companies, and those unfamiliar with the process for Nov. 4-5, 2010, in Lansdowne, Va.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The workshop, in collaboration with the Drug Information Association, will focus on the process used by the FDA to grant a special status, known as orphan designation, for drug products intended to treat rare diseases. Similar workshops were held earlier this year in Claremont, Calif., and Minneapolis.

Orphan drugs are either drug or biologic products used to treat diseases or conditions affecting fewer than 200,000 people in the United States. Orphan drug designation is available for drugs already approved for another disease or condition or for experimental drugs that have not been previously approved.

During the workshop, participants will propose a specific drug for a specific rare disease and work on an orphan designation application to submit to the FDA at the conclusion of the workshop. FDA staff will provide one-on-one guidance to help participants develop strong applications.

To obtain orphan drug designation, drugs must be for the treatment, prevention or diagnosis of a rare disease or condition. Designation also requires there be a scientific rationale for expecting the proposed drug to be effective in the treatment, prevention, or diagnosis of that disease or condition.

Orphan designation qualifies the applicant to receive certain benefits, such as tax credits and marketing incentives, from the federal government in exchange for developing the drug. After designation, the orphan drug may then be submitted for review through the FDA marketing approval process, which evaluates the drug for safety and efficacy.

Since 1983, when the Orphan Drug Act was passed, the FDA has received 3,212 applications for orphan drug designation and has granted orphan drug designation to about 2,250 drugs, of which 361 have become approved products.

For more information:

  • DIA/FDA: Orphan Drug Designation Workshop Brochure

http://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/UCM215487.pdf

  • Developing Products for Rare Diseases and Conditions

http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm

  • Drug Information Association

http://www.diahome.org/DIAHome/Home.aspx

Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems Schedules Fourth Quarter FY2010 News Release and Conference Call
2. Misonix Schedules Fourth Quarter and Fiscal 2010 Financial Results Conference Call; September 28, 2010 at 4:30 p.m. Eastern
3. Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results
4. Varian Medical Systems Schedules Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010
5. Sunridge Schedules European Meetings
6. Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010
7. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
8. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
9. VirtualScopics Schedules Second Quarter 2010 Earnings Announcement
10. Thoratec Schedules Second Quarter Conference Call, Webcast
11. Alere Inc. Schedules Conference Call for 10:00 a.m. ET July 28, 2010 to Discuss Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... - bioLytical lanza el INSTI HIV Self Test ... Continue Reading ... New: ... , , bioLytical Laboratories (la "Compañía"), ... está expandiendo el lanzamiento de su INSTI HIV Self Test  a África con ...
(Date:12/2/2016)... North America held the largest share in the ... aged population and demand for remote monitoring ECG devices. On ... region is expected to witness the highest growth rate during ... Company (U.S.), Becton, Dickinson and Company (U.S.), Medtronic plc ( ... Netherlands ) and Mindray Medical International Limited ( ...
(Date:12/2/2016)... Research and Markets has announced the addition of the ... 2022" report to their offering. ... , The global ultrasound device ... expected to grow at a CAGR of 5.5% during 2016-2022. Based on ... the forecast period, a CAGR of 8.8% in the global market. Among ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
(Date:12/2/2016)... ... ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, has published ... Yisrayl says this generation, known as the Last Generation, started in 1934 A.Y. (After ... up exactly with Bible Prophecy – a protected way for those who will believe. ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a ... applications, was named the best Sales Team of 2016 as part of the ... today by the Software & Information Industry Association (SIIA), the principal trade association ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... that they now offer a comprehensive in-house dental plan for all patients. Understanding ... developed a plan that gives patients a number of perks, including discounts on ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center ... has announced the opening of a new residential mental health treatment program in ... health issues such as severe anxiety, depression, bi-polar disorder, and other related issues. ...
Breaking Medicine News(10 mins):